Article may be outdated

This article is 10 days old. Some details may have changed since publication.

HCPLive·3 min read·hard

ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD

P
Patrick Campbell
ZEUS: Ziltivekimab Fails to Reduce Cardiovascular Events in ASCVD and CKD
✦AI Summary

The phase 3 ZEUS trial found that the drug ziltivekimab failed to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and chronic kidney disease. Despite lowering inflammatory biomarkers, the treatment did not provide the expected clinical benefit compared to a placebo.

Why it matters

The failure of this trial highlights the complexities of targeting inflammation to treat heart disease and underscores the necessity of rigorous clinical testing.

✦Dive DeeperCreate a free account to unlock

Ziltivekimab, an interleukin-6 (IL-6) inhibitor, did not reduce cardiovascular events compared with placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation in the phase 3 ZEUS trial, according to results presented at the American Heart Association (AHA) Scientific Sessions 2026 and published in the New England Journal of Medicine.1

Ziltivekimab, a monoclonal antibody neutralizing the IL-6 ligand, lowered high-sensitivity C-reactive protein (hsCRP) and other inflammatory biomarkers in a phase 2 study of patients with CKD. The ZEUS rationale drew on mendelian randomization data implicating IL-6 signaling in atherosclerosis and on CANTOS, in which interleukin-1β inhibition with canakinumab lowered recurrent cardiovascular event rates.1

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in